Dorsal myelopathy after nelarabine and intrathecal methotrexate therapy

Pediatr Int. 2022 Jan;64(1):e15334. doi: 10.1111/ped.15334.

Authors

Fumi Sawamura¹, Jun Natsume^{1

2

3}, Tomohiko Nakata^{1

3}, Hideki Muramatsu¹, Yoshiyuki Takahashi¹

Affiliations

¹ Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
² Department of Developmental Disability Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
³ Brain and Mind Research Center, Nagoya University, Nagoya, Japan.

PMID: 36331221
DOI: 10.1111/ped.15334

No abstract available

Keywords: acute lymphoblastic leukemia; methotrexate; myelopathy; nelarabine.

MeSH terms

Arabinonucleosides
Humans
Injections, Spinal
Methotrexate* / adverse effects
Spinal Cord Diseases* / chemically induced
Spinal Cord Diseases* / diagnosis

Substances

nelarabine
Methotrexate
Arabinonucleosides